# Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.

> **NCT06659653** · EARLY_PHASE1 · RECRUITING · sponsor: **Tan Jie** · enrollment: 18 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** PRG2302

## Key facts

- **NCT ID:** NCT06659653
- **Lead sponsor:** Tan Jie
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-24
- **Primary completion:** 2027-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06659653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06659653, "Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06659653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*